Dupixent Special Drug Use Investigation for long term use (Prurigo nodularis)(Chronic spontaneous urticaria)

Dupixent Special Drug Use Investigation for long term use (Prurigo nodularis)(Chronic spontaneous urticaria) - Dupixent Special Drug Use Investigation for long term use (Prurigo nodularis)(Chronic spontaneous urticaria)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051970

Enrollment

200

Registered

2023-08-25

Start date

2023-12-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prurigo nodularis, Chronic spontaneous urticaria

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients with prurigo nodular not adequately controlled with existing therapies or Patients with chrinic spontaneus urticaria not adequately controlled with existing therapies -Patients who newly start receiving the treatment with Dupixent -Patients who can provide informed consent (in parson or legal representative)

Exclusion criteria

Exclusion criteria: Subjects who are participating in or have been registered for clinical trials with therapeutic intervention to Dupixent

Design outcomes

Primary

Measure	Time frame
Safety:Incidence rates of adverse drug reactions, Safety specification items of Dupixent Effectiveness (PN):Investigator's Global Assessment for PN-Stage(IGA PN-S), Investigator's Global Assessment for PN-Activity(IGA PN-A), Worst-itch numeric rating scale(WI-NRS) Effectiveness (CSU): Investigator's Global Assessment	—

Countries

Japan

Contacts

Public ContactPublic contact for Drug use surveillance -

Sanofi K.K. Post-authorization regulatory studies, Medical Affairs

Sanofi_Medical@sanofi.com03-6301-3867

Outcome results